Shiyi Investment

Lin Lijun founded Shiyi Investment in 2015 as a Shanghai-based early-stage asset manager. The firm targets seed and Series A rounds in enterprise software, artificial intelligence, digital health, and industrial technology. Its investment approach is thesis-driven, with a concentration on companies building infrastructure-layer technologies for China's industrial and consumer digitization.

Shiyi Investment focuses on seed and early-stage venture rounds, typically entering at seed or Series A. The firm reserves capital for follow-on participation through Series B, maintaining concentrated positions across a portfolio of approximately 15 to 25 active investments. This stage focus reflects the founder's research-intensive approach to de-risking early-stage technology bets.

Publicly reported portfolio companies include Xbiome, an AI-driven drug discovery platform, and Mech-Mind Robotics, an industrial robotics developer (per public record). The broader portfolio spans enterprise software, artificial intelligence, digital health, and industrial technology. The firm typically does not disclose its full portfolio, consistent with the private nature of its early-stage investments.

Yes. Shiyi Investment participates in syndicated deals alongside domestic Chinese venture funds including Qiming Venture Partners and Sequoia Capital China on select investments. This co-investment model extends the firm's sourcing reach across the Shanghai, Beijing, and Shenzhen startup ecosystems without requiring a large proprietary origination team.

Shiyi Investment sources deals primarily from China's three core technology hubs: Shanghai, Beijing, and Shenzhen. Its sourcing network includes relationships with domestic venture syndicates, university research labs, and technology incubators. The firm's research-intensive diligence model — embedding PhD-level technical analysts — creates proprietary sourcing advantages in frontier technologies like AI-driven drug discovery and autonomous industrial systems.

Shiyi Investment operates with a compact team led by Founding Partner Lin Lijun and a group of sector-specialist partners with backgrounds in computer science and life sciences. The firm embeds technical PhD-level analysts within diligence teams, a structural feature that supports its deep-tech investment thesis. Total headcount and assets under management are not publicly disclosed.

Shiyi Investment is structured as an independent institutional asset manager, not a family office. It raises discretionary capital from institutional limited partners and invests it across early-stage venture opportunities. The firm's founding in 2015 by Lin Lijun positioned it to capture the structural shift toward indigenous Chinese enterprise technology and healthcare innovation.